Takeaways: Itovebi’s addition to Québec’s RAMQ list means eligible patients with advanced HR‑positive, HER2‑negative, PIK3CA‑mutated breast cancer can now access a targeted pill that, in the INAVO120 ...
Takeaways: Grey Matter’s focused ultrasound platform aims to offer a non‑invasive option for people whose depression hasn’t improved with medications or therapy, by precisely stimulating deep brain ci...
Takeaways: The acquisition turns Jamieson into Kirin’s North American foundation alongside Blackmores and FANCL, creating a multi‑brand global preventative health portfolio that can leverag...
Takeaways: By combining a TSXV listing with a Health Canada-accepted ANDS for a domestically made generic Ozempic, Vimy is positioning itself to compete in a fast-growing, high-value GLP-1 marke...
Takeaways: The C-POST data – 68% reduction in recurrence or death versus placebo – gives Regeneron a strong clinical story to push Libtayo earlier in the treatment pathway,...
Takeaways: The availability of a nasal spray should broaden the addressable market for emergency epinephrine by reducing needle anxiety and administration hesitation, potentially increasing carr...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: The main market signal is strategic rather than commercial: Health Canada’s clearance, alongside PHAC’s collaboration with Moderna, helps de-risk the company’s mRNA infectious-disease...
